[World-wide status of hepatitis B vaccination 1998]

Area of Science:

• Public Health
• Vaccinology
• Preventive Medicine

Background:

• The World Health Organization (WHO) recommended universal inclusion of the Hepatitis B (HB) vaccine in childhood immunization programs in 1991.
• By 1998, over 90 countries had integrated the HB vaccine into national programs, reaching approximately half the world's children and 70% of carriers.
• The WHO set a target to prevent 80% of new Hepatitis B virus (HBV) carriers in children by 2001 through routine immunization.

Purpose of the Study:

• To assess the effectiveness of the HB vaccine in preventing chronic carrier states.
• To evaluate the impact of widespread HB vaccination on public health outcomes, including liver cancer reduction.
• To identify challenges in achieving global access to the HB vaccine.

Main Methods:

• Population-based studies were conducted across multiple countries to determine vaccine efficacy.
• Analysis of national immunization program data to track vaccine uptake and coverage.
• Review of epidemiological data on HBV carrier rates and liver cancer incidence in immunized populations.

Main Results:

• The HB vaccine demonstrated 85% to 95% effectiveness in preventing the chronic carrier state in population-based studies.
• Studies in Taiwan showed a direct reduction in liver cancer among immunized children.
• Significant progress has been made in global vaccine adoption, but equitable access remains an issue.

Conclusions:

• The HB vaccine is a highly effective tool for preventing chronic HBV infection and reducing liver cancer incidence in children.
• Widespread implementation of routine childhood immunization programs is crucial for controlling HBV transmission.
• Developing sustainable financial mechanisms is essential to ensure all children, particularly in low-income countries, benefit from this life-saving vaccine.